Latest Breaking News On - வணிக வலைப்பின்னல் ஆன் - Page 1 : comparemela.com

Bloomberg TV and other stations “To Be Announced.” Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma (NASDAQ: AZRX) talks to the “New To The Street’s” TV audience about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.   James Sapirstein, CEO, AZRX states, “I am excited to be a guest on the ‘New To The Street’ TV program. The show has had a tremendous track record; I am happy to join the ranks. I look forward to educating viewers about AzurRx BioPharma - about our business, our biopharmaceutical products and therapies, and our future to grow the Company.”

Vincent carusoAzurrx biopharmaBryan johnsonJames sapirsteinJane kingExchange commissionBusiness network onSecurities exchangeAzurrx biopharma incNewsmax televisionNew to the streetCheckpoint inhibitor associatedNielsen ratedLooking statements disclaimerSecurities actSecurities exchange act